{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T02:39:40Z","timestamp":1777084780832,"version":"3.51.4"},"reference-count":82,"publisher":"American Association for Laboratory Animal Science","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Modeling disease in rodents is essential for preclinical research, particularly in the development of drugs and therapies. Traditional disease modeling approaches often rely on invasive and stressful procedures such as repeated injections and\/or surgical approaches. These methods raise welfare concerns and can introduce stress-related variables that compromise model reliability. Cuprizone (CPZ) is a copper-chelating compound widely used to induce CNS demyelination in mice over a 6-week period via incorporation into ground rodent chow. However, the presumed adverse taste of CPZ reduces food intake, resulting in weight loss, inconsistent consumption, and variable levels of demyelination, complicating disease comparison. To address this, we proposed that mixing CPZ into peanut butter (CPZ-PB) would promote voluntary intake, standardize daily dosing, and minimize weight loss, while maintaining effective demyelination. Thirty mice were divided into control, CPZ-PB, or CPZ-chow groups and received treatment daily for 6 weeks. Body weight and CPZ intake were recorded daily. The effect of demyelination through mechanical allodynia was assessed via the dynamic plantar aesthesiometer. Immunohistochemical analysis of myelin proteins and astrocyte activation was conducted on the brain and spinal cord after 6 weeks of treatment. Voluntary consumption of CPZ-PB successfully ameliorated weight loss concerns and achieved consistent daily CPZ dosing. Behavioral and immunohistochemical analyses confirmed effective demyelination comparable to traditional CPZ-chow methods. This study introduces an improved CPZ administration strategy that enhances animal welfare and provides a more reliable model for demyelination research.<\/jats:p>","DOI":"10.30802\/aalas-jaalas-25-151","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:54:11Z","timestamp":1771210451000},"page":"270-278","source":"Crossref","is-referenced-by-count":0,"title":["Cuprizone in Peanut Butter: An Alternative Method of Cuprizone Administration to Model Demyelination of the Central Nervous System"],"prefix":"10.30802","volume":"65","author":[{"given":"Brooke","family":"Hawker","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Centre for Brain Research, School of Medical Science, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Chiddicks","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Centre for Brain Research, School of Medical Science, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Centre for Brain Research, School of Medical Science, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronwen","family":"Connor","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Centre for Brain Research, School of Medical Science, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"McCaughey-Chapman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, Centre for Brain Research, School of Medical Science, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"12258","reference":[{"issue":"1","key":"bib1","series-title":"Lab Anim Res.","first-page":"18","article-title":"Role of animal models in biomedical research: a review","volume":"38","author":"Mukherjee P","year":"2022","unstructured":"Mukherjee P, Roy S, Ghosh D, Nandi SK. Role of animal models in biomedical research: a review. Lab Anim Res. 2022;38(1):18."},{"issue":"1","key":"bib2","series-title":"Biochem Pharmacol.","first-page":"140","article-title":"Animal models of CNS disorders","volume":"87","author":"McGonigle P","year":"2014","unstructured":"McGonigle P. Animal models of CNS disorders. Biochem Pharmacol. 2014;87(1):140\u2013149."},{"issue":"1","key":"bib3","series-title":"Contemp Top Lab Anim Sci.","first-page":"17","article-title":"Stress produced by gavage administration in the rat","volume":"39","author":"Brown AP","year":"2000","unstructured":"Brown AP, Dinger N, Levine BS. Stress produced by gavage administration in the rat. Contemp Top Lab Anim Sci. 2000;39(1):17\u201321."},{"issue":"5","key":"bib4","series-title":"Lab Anim (NY).","first-page":"129","article-title":"The effects of repeated oral gavage on the health of male CD-1 mice","volume":"41","author":"Arantes-Rodrigues R","year":"2012","unstructured":"Arantes-Rodrigues R, Henriques A, Pinto-Leite R, et al. The effects of repeated oral gavage on the health of male CD-1 mice. Lab Anim (NY). 2012;41(5):129\u2013134."},{"issue":"5","key":"bib5","series-title":"Lab Anim.","first-page":"470","article-title":"Differential anxiety-like responses in NOD\/ShiLtJ and C57BL\/6J mice following experimental autoimmune encephalomyelitis induction and oral gavage","volume":"52","author":"Kocovski P","year":"2018","unstructured":"Kocovski P, Dang PT, D\u2019Souza CS, Stamper CE, Hale MW, Orian JM. Differential anxiety-like responses in NOD\/ShiLtJ and C57BL\/6J mice following experimental autoimmune encephalomyelitis induction and oral gavage. Lab Anim. 2018;52(5):470\u2013478."},{"key":"bib6","series-title":"Pharmacol Biochem Behav.","first-page":"28","article-title":"Alternative method of oral administration by peanut butter pellet formulation results in target engagement of BACE1 and attenuation of gavage-induced stress responses in mice","volume":"126","author":"Gonzales C","year":"2014","unstructured":"Gonzales C, Zaleska MM, Riddell DR, et al. Alternative method of oral administration by peanut butter pellet formulation results in target engagement of BACE1 and attenuation of gavage-induced stress responses in mice. Pharmacol Biochem Behav. 2014;126:28\u201335."},{"key":"bib7","series-title":"J Vis Exp.","first-page":"10.3791\/62775","article-title":"Self-administration of drugs in mouse models of feeding and obesity","volume":"172","author":"Zapata RC","year":"2021","unstructured":"Zapata RC, Zhang D, Chaudry B, Osborn O. Self-administration of drugs in mouse models of feeding and obesity. J Vis Exp. 2021;172:10.3791\/62775."},{"key":"bib8","series-title":"J Pharmacol Toxicol Methods.","first-page":"106948","article-title":"Peanut butter as an alternative dose delivery method to prevent strain-dependent orogastric gavage-induced stress in mouse teratogenicity studies","volume":"107","author":"Warren MR","year":"2021","unstructured":"Warren MR, Radulescu A, Dornbos P, et al. Peanut butter as an alternative dose delivery method to prevent strain-dependent orogastric gavage-induced stress in mouse teratogenicity studies. J Pharmacol Toxicol Methods. 2021;107:106948."},{"issue":"1","key":"bib9","series-title":"Lab Anim.","first-page":"76","article-title":"An alternative method for oral drug administration by voluntary intake in male and female mice","volume":"55","author":"Teixeira-Santos L","year":"2021","unstructured":"Teixeira-Santos L, Albino-Teixeira A, Pinho D. An alternative method for oral drug administration by voluntary intake in male and female mice. Lab Anim. 2021;55(1):76\u201380."},{"issue":"4","key":"bib10","series-title":"Lab Anim.","first-page":"318","article-title":"A method for reliable voluntary oral administration of a fixed dosage (mg\/kg) of chronic daily medication to rats","volume":"46","author":"Corbett A","year":"2012","unstructured":"Corbett A, McGowin A, Sieber S, Flannery T, Sibbitt B. A method for reliable voluntary oral administration of a fixed dosage (mg\/kg) of chronic daily medication to rats. Lab Anim. 2012;46(4):318\u2013324."},{"issue":"4","key":"bib11","series-title":"Cells.","first-page":"843","article-title":"The cuprizone model: dos and do nots","volume":"9","author":"Zhan J","year":"2020","unstructured":"Zhan J, Mann T, Joost S, Behrangi N, Frank M, Kipp M. The cuprizone model: dos and do nots. Cells. 2020;9(4):843."},{"issue":"1-2","key":"bib12","series-title":"J Neuroimmunol.","first-page":"38","article-title":"Microglial\/macrophage accumulation during cuprizone-induced demyelination in C57BL\/6 mice","volume":"92","author":"Hiremath MM","year":"1998","unstructured":"Hiremath MM, Saito Y, Knapp GW, Ting JPY, Suzuki K, Matsushima GK. Microglial\/macrophage accumulation during cuprizone-induced demyelination in C57BL\/6 mice. J Neuroimmunol. 1998;92(1-2):38\u201349."},{"key":"bib13","series-title":"Front Cell Neurosci.","first-page":"73","article-title":"Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned","volume":"8","author":"Gudi V","year":"2014","unstructured":"Gudi V, Gingele S, Skripuletz T, Stangel M. Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. Front Cell Neurosci. 2014;8:73."},{"issue":"1","key":"bib14","series-title":"Acta Neuropathol Commun.","first-page":"94","article-title":"Blood-brain barrier hyperpermeability precedes demyelination in the cuprizone model","volume":"5","author":"Berghoff SA","year":"2017","unstructured":"Berghoff SA, D\u00fcking T, Spieth L, et al. Blood-brain barrier hyperpermeability precedes demyelination in the cuprizone model. Acta Neuropathol Commun. 2017;5(1):94."},{"issue":"4","key":"bib15","series-title":"J Neurocytol.","first-page":"413","article-title":"Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice","volume":"1","author":"Blakemore WF","year":"1972","unstructured":"Blakemore WF. Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice. J Neurocytol. 1972;1(4):413\u2013426."},{"issue":"4-5","key":"bib16","series-title":"Mol Cell Neurosci.","first-page":"220","article-title":"Gene expression in brain during cuprizone-induced demyelination and remyelination","volume":"12","author":"Morell P","year":"1998","unstructured":"Morell P, Barrett CV, Mason JL, et al. Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol Cell Neurosci. 1998;12(4-5):220\u2013227."},{"issue":"12","key":"bib17","series-title":"Histol Histopathol.","first-page":"1585","article-title":"De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected","volume":"26","author":"Skripuletz T","year":"2011","unstructured":"Skripuletz T, Gudi V, Hackstette D, Stangel M. De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol Histopathol. 2011;26(12):1585\u20131597."},{"issue":"13","key":"bib18","series-title":"Int J Mol Sci.","first-page":"10564","article-title":"The cuprizone mouse model: a comparative study of cuprizone formulations from different manufacturers","volume":"24","author":"Beecken M","year":"2023","unstructured":"Beecken M, Baumann L, Vankriekelsvenne E, et al. The cuprizone mouse model: a comparative study of cuprizone formulations from different manufacturers. Int J Mol Sci. 2023;24(13):10564."},{"issue":"1","key":"bib19","series-title":"Metallomics.","first-page":"mfad072","article-title":"Evidence for decreased copper associated with demyelination in the corpus callosum of cuprizone-treated mice","volume":"16","author":"Hilton JBW","year":"2024","unstructured":"Hilton JBW, Kysenius K, Liddell JR, et al. Evidence for decreased copper associated with demyelination in the corpus callosum of cuprizone-treated mice. Metallomics. 2024;16(1):mfad072."},{"issue":"8","key":"bib20","series-title":"Neurochem Res.","first-page":"1029","article-title":"Biochemical changes in cuprizone-induced spongiform encephalopathy","volume":"8","author":"Carey EM","year":"1983","unstructured":"Carey EM, Freeman NM. Biochemical changes in cuprizone-induced spongiform encephalopathy. Neurochem Res. 1983;8(8):1029\u20131044."},{"issue":"1","key":"bib21","series-title":"Neurosci Res.","first-page":"32","article-title":"Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication","volume":"72","author":"Steelman AJ","year":"2012","unstructured":"Steelman AJ, Thompson JP, Li J. Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication. Neurosci Res. 2012;72(1):32\u201342."},{"issue":"1","key":"bib22","series-title":"Mol Med.","first-page":"628","article-title":"Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice","volume":"18","author":"Hagemeyer N","year":"2012","unstructured":"Hagemeyer N, Boretius S, Ott C, et al. Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice. Mol Med. 2012;18(1):628\u2013635."},{"issue":"4","key":"bib23","series-title":"J Mol Neurosci.","first-page":"617","article-title":"Cuprizone-containing pellets are less potent to induce consistent demyelination in the corpus callosum of C57BL\/6 mice","volume":"61","author":"Hochstrasser T","year":"2017","unstructured":"Hochstrasser T, Exner GL, Nyamoya S, Schmitz C, Kipp M. Cuprizone-containing pellets are less potent to induce consistent demyelination in the corpus callosum of C57BL\/6 mice. J Mol Neurosci. 2017;61(4):617\u2013624."},{"issue":"13","key":"bib24","series-title":"Cell Mol Life Sci.","first-page":"1502","article-title":"Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment","volume":"62","author":"Zatta P","year":"2005","unstructured":"Zatta P, Raso M, Zambenedetti P, et al. Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment. Cell Mol Life Sci. 2005;62(13):1502\u20131513."},{"issue":"20","key":"bib25","series-title":"Eur Rev Med Pharmacol Sci.","first-page":"2711","article-title":"Cuprizone-induced demyelination in Wistar rats; electrophysiological and histological assessment","volume":"17","author":"Basoglu H","year":"2013","unstructured":"Basoglu H, Boylu NT, Kose H. Cuprizone-induced demyelination in Wistar rats; electrophysiological and histological assessment. Eur Rev Med Pharmacol Sci. 2013;17(20):2711\u20132717."},{"issue":"4","key":"bib26","series-title":"ASN Neuro.","first-page":"1759091417725174","article-title":"An alternative cuprizone-induced demyelination and remyelination mouse model","volume":"9","author":"Zhen W","year":"2017","unstructured":"Zhen W, Liu A, Lu J, Zhang W, Tattersall D, Wang J. An alternative cuprizone-induced demyelination and remyelination mouse model. ASN Neuro. 2017;9(4):1759091417725174."},{"issue":"4","key":"bib27","series-title":"Behav Res Methods.","first-page":"1149","article-title":"Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses","volume":"41","author":"Faul F","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149\u20131160."},{"issue":"61","key":"bib28","series-title":"J Vis Exp.","first-page":"3393","article-title":"Chronic constriction of the sciatic nerve and pain hypersensitivity testing in rats","author":"Austin PJ","year":"2012","unstructured":"Austin PJ, Wu A, Moalem-Taylor G. Chronic constriction of the sciatic nerve and pain hypersensitivity testing in rats. J Vis Exp. 2012;(61):3393."},{"issue":"3","key":"bib29","series-title":"Brain Pathol.","first-page":"329","article-title":"Quantifying the early stages of remyelination following cuprizone\u2010induced demyelination","volume":"13","author":"Stidworthy MF","year":"2003","unstructured":"Stidworthy MF, Genoud S, Suter U, Mantei N, Franklin RJM. Quantifying the early stages of remyelination following cuprizone\u2010induced demyelination. Brain Pathol. 2003;13(3):329\u2013339."},{"key":"bib30","series-title":"Management of Animal Care and Use Programs in Research, Education, and Testing","first-page":"639","article-title":"Feed and bedding","author":"Carter RL","year":"2017","unstructured":"Carter RL, Lipman NS. Feed and bedding. In: Weichbrod RH, Thomson GAH, Norton JN, editors. Management of Animal Care and Use Programs in Research, Education, and Testing. CRC Press 2017. p. 639\u2013654."},{"issue":"2","key":"bib31","series-title":"J Prev Med Hyg.","first-page":"E255","article-title":"Ethical considerations regarding animal experimentation","volume":"63","author":"Kiani AK","year":"2022","unstructured":"Kiani AK, Pheby D, Henehan G, et al. Ethical considerations regarding animal experimentation. J Prev Med Hyg. 2022;63(2):E255\u2013E266."},{"issue":"5","key":"bib32","series-title":"Brain Behav Immun.","first-page":"699","article-title":"Pain hypersensitivity in rats with experimental autoimmune neuritis, an animal model of human inflammatory demyelinating neuropathy","volume":"21","author":"Moalem-Taylor G","year":"2007","unstructured":"Moalem-Taylor G, Allbutt HN, Iordanova MD, Tracey DJ. Pain hypersensitivity in rats with experimental autoimmune neuritis, an animal model of human inflammatory demyelinating neuropathy. Brain Behav Immun. 2007;21(5):699\u2013710."},{"issue":"1","key":"bib33","series-title":"Brain Behav Immun.","first-page":"92","article-title":"Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental multiple sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy","volume":"23","author":"Sloane E","year":"2009","unstructured":"Sloane E, Ledeboer A, Seibert W, et al. Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental multiple sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. Brain Behav Immun. 2009;23(1):92\u2013100."},{"key":"bib34","series-title":"Adv Neurol.","first-page":"289","article-title":"Hyperexcitability of pathologically myelinated axons and positive symptoms in multiple sclerosis","volume":"31","author":"Rasminsky M","year":"1981","unstructured":"Rasminsky M. Hyperexcitability of pathologically myelinated axons and positive symptoms in multiple sclerosis. Adv Neurol. 1981;31:289\u2013297."},{"issue":"2","key":"bib35","series-title":"J Pharmacol Sci.","first-page":"93","article-title":"LPA5 signaling is involved in multiple sclerosis-mediated neuropathic pain in the cuprizone mouse model","volume":"136","author":"Tsukahara R","year":"2018","unstructured":"Tsukahara R, Yamamoto S, Yoshikawa K, et al. LPA5 signaling is involved in multiple sclerosis-mediated neuropathic pain in the cuprizone mouse model. J Pharmacol Sci. 2018;136(2):93\u201396."},{"issue":"12","key":"bib36","series-title":"Brain Sci.","first-page":"1687","article-title":"Sex differences in the behavioural aspects of the cuprizone-induced demyelination model in mice","volume":"12","author":"Paton KF","year":"2022","unstructured":"Paton KF, Hong S, Biggerstaff A, Kivell BM. Sex differences in the behavioural aspects of the cuprizone-induced demyelination model in mice. Brain Sci. 2022;12(12):1687."},{"issue":"6","key":"bib37","series-title":"Neuropathol Appl Neurobiol.","first-page":"676","article-title":"Lack of cuprizone-induced demyelination in the murine spinal cord despite oligodendroglial alterations substantiates the concept of site-specific susceptibilities of the central nervous system","volume":"37","author":"Herder V","year":"2011","unstructured":"Herder V, Hansmann F, Stangel M, Skripuletz T, Baumg\u00e4rtner W, Beineke A. Lack of cuprizone-induced demyelination in the murine spinal cord despite oligodendroglial alterations substantiates the concept of site-specific susceptibilities of the central nervous system. Neuropathol Appl Neurobiol. 2011;37(6):676\u2013684."},{"key":"bib38","series-title":"Front Mol Neurosci.","first-page":"1007889","article-title":"The role of astrocytes in neuropathic pain","volume":"15","author":"Cheng T","year":"2022","unstructured":"Cheng T, Xu Z, Ma X. The role of astrocytes in neuropathic pain. Front Mol Neurosci. 2022;15:1007889."},{"issue":"2","key":"bib39","series-title":"Drug Dev Ind Pharm.","first-page":"221","article-title":"Enhanced oral bioavailability of a poorly water soluble drug PNU\u201091325 by supersaturatable formulations","volume":"30","author":"Gao P","year":"2004","unstructured":"Gao P, Guyton ME, Huang T, Bauer JM, Stefanski KJ, Lu Q. Enhanced oral bioavailability of a poorly water soluble drug PNU\u201091325 by supersaturatable formulations. Drug Dev Ind Pharm. 2004;30(2):221\u2013229."},{"issue":"39","key":"bib40","series-title":"Curr Pharm Des.","first-page":"3212","article-title":"A recent review on bio-availability enhancement of poorly water-soluble drugs by using bioenhancer and nanoparticulate drug delivery system","volume":"28","author":"Kumar M","year":"2022","unstructured":"Kumar M, Kumar D, Kumar S, Kumar A, Mandal UK. A recent review on bio-availability enhancement of poorly water-soluble drugs by using bioenhancer and nanoparticulate drug delivery system. Curr Pharm Des. 2022;28(39):3212\u20133224."},{"issue":"10","key":"bib41","series-title":"Animals (Basel).","first-page":"754","article-title":"The 3Rs and humane experimental technique: implementing change","volume":"9","author":"Hubrecht RC","year":"2019","unstructured":"Hubrecht RC, Carter E. The 3Rs and humane experimental technique: implementing change. Animals (Basel). 2019;9(10):754."},{"issue":"1","key":"bib1","series-title":"Lab Anim Res.","first-page":"18","article-title":"Role of animal models in biomedical research: a review","volume":"38","author":"Mukherjee P","year":"2022","unstructured":"Mukherjee P, Roy S, Ghosh D, Nandi SK. Role of animal models in biomedical research: a review. Lab Anim Res. 2022;38(1):18."},{"issue":"1","key":"bib2","series-title":"Biochem Pharmacol.","first-page":"140","article-title":"Animal models of CNS disorders","volume":"87","author":"McGonigle P","year":"2014","unstructured":"McGonigle P. Animal models of CNS disorders. Biochem Pharmacol. 2014;87(1):140\u2013149."},{"issue":"1","key":"bib3","series-title":"Contemp Top Lab Anim Sci.","first-page":"17","article-title":"Stress produced by gavage administration in the rat","volume":"39","author":"Brown AP","year":"2000","unstructured":"Brown AP, Dinger N, Levine BS. Stress produced by gavage administration in the rat. Contemp Top Lab Anim Sci. 2000;39(1):17\u201321."},{"issue":"5","key":"bib4","series-title":"Lab Anim (NY).","first-page":"129","article-title":"The effects of repeated oral gavage on the health of male CD-1 mice","volume":"41","author":"Arantes-Rodrigues R","year":"2012","unstructured":"Arantes-Rodrigues R, Henriques A, Pinto-Leite R, et al. The effects of repeated oral gavage on the health of male CD-1 mice. Lab Anim (NY). 2012;41(5):129\u2013134."},{"issue":"5","key":"bib5","series-title":"Lab Anim.","first-page":"470","article-title":"Differential anxiety-like responses in NOD\/ShiLtJ and C57BL\/6J mice following experimental autoimmune encephalomyelitis induction and oral gavage","volume":"52","author":"Kocovski P","year":"2018","unstructured":"Kocovski P, Dang PT, D\u2019Souza CS, Stamper CE, Hale MW, Orian JM. Differential anxiety-like responses in NOD\/ShiLtJ and C57BL\/6J mice following experimental autoimmune encephalomyelitis induction and oral gavage. Lab Anim. 2018;52(5):470\u2013478."},{"key":"bib6","series-title":"Pharmacol Biochem Behav.","first-page":"28","article-title":"Alternative method of oral administration by peanut butter pellet formulation results in target engagement of BACE1 and attenuation of gavage-induced stress responses in mice","volume":"126","author":"Gonzales C","year":"2014","unstructured":"Gonzales C, Zaleska MM, Riddell DR, et al. Alternative method of oral administration by peanut butter pellet formulation results in target engagement of BACE1 and attenuation of gavage-induced stress responses in mice. Pharmacol Biochem Behav. 2014;126:28\u201335."},{"key":"bib7","series-title":"J Vis Exp.","first-page":"10.3791\/62775","article-title":"Self-administration of drugs in mouse models of feeding and obesity","volume":"172","author":"Zapata RC","year":"2021","unstructured":"Zapata RC, Zhang D, Chaudry B, Osborn O. Self-administration of drugs in mouse models of feeding and obesity. J Vis Exp. 2021;172:10.3791\/62775."},{"key":"bib8","series-title":"J Pharmacol Toxicol Methods.","first-page":"106948","article-title":"Peanut butter as an alternative dose delivery method to prevent strain-dependent orogastric gavage-induced stress in mouse teratogenicity studies","volume":"107","author":"Warren MR","year":"2021","unstructured":"Warren MR, Radulescu A, Dornbos P, et al. Peanut butter as an alternative dose delivery method to prevent strain-dependent orogastric gavage-induced stress in mouse teratogenicity studies. J Pharmacol Toxicol Methods. 2021;107:106948."},{"issue":"1","key":"bib9","series-title":"Lab Anim.","first-page":"76","article-title":"An alternative method for oral drug administration by voluntary intake in male and female mice","volume":"55","author":"Teixeira-Santos L","year":"2021","unstructured":"Teixeira-Santos L, Albino-Teixeira A, Pinho D. An alternative method for oral drug administration by voluntary intake in male and female mice. Lab Anim. 2021;55(1):76\u201380."},{"issue":"4","key":"bib10","series-title":"Lab Anim.","first-page":"318","article-title":"A method for reliable voluntary oral administration of a fixed dosage (mg\/kg) of chronic daily medication to rats","volume":"46","author":"Corbett A","year":"2012","unstructured":"Corbett A, McGowin A, Sieber S, Flannery T, Sibbitt B. A method for reliable voluntary oral administration of a fixed dosage (mg\/kg) of chronic daily medication to rats. Lab Anim. 2012;46(4):318\u2013324."},{"issue":"4","key":"bib11","series-title":"Cells.","first-page":"843","article-title":"The cuprizone model: dos and do nots","volume":"9","author":"Zhan J","year":"2020","unstructured":"Zhan J, Mann T, Joost S, Behrangi N, Frank M, Kipp M. The cuprizone model: dos and do nots. Cells. 2020;9(4):843."},{"issue":"1-2","key":"bib12","series-title":"J Neuroimmunol.","first-page":"38","article-title":"Microglial\/macrophage accumulation during cuprizone-induced demyelination in C57BL\/6 mice","volume":"92","author":"Hiremath MM","year":"1998","unstructured":"Hiremath MM, Saito Y, Knapp GW, Ting JPY, Suzuki K, Matsushima GK. Microglial\/macrophage accumulation during cuprizone-induced demyelination in C57BL\/6 mice. J Neuroimmunol. 1998;92(1-2):38\u201349."},{"key":"bib13","series-title":"Front Cell Neurosci.","first-page":"73","article-title":"Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned","volume":"8","author":"Gudi V","year":"2014","unstructured":"Gudi V, Gingele S, Skripuletz T, Stangel M. Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. Front Cell Neurosci. 2014;8:73."},{"issue":"1","key":"bib14","series-title":"Acta Neuropathol Commun.","first-page":"94","article-title":"Blood-brain barrier hyperpermeability precedes demyelination in the cuprizone model","volume":"5","author":"Berghoff SA","year":"2017","unstructured":"Berghoff SA, D\u00fcking T, Spieth L, et al. Blood-brain barrier hyperpermeability precedes demyelination in the cuprizone model. Acta Neuropathol Commun. 2017;5(1):94."},{"issue":"4","key":"bib15","series-title":"J Neurocytol.","first-page":"413","article-title":"Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice","volume":"1","author":"Blakemore WF","year":"1972","unstructured":"Blakemore WF. Observations on oligodendrocyte degeneration, the resolution of status spongiosus and remyelination in cuprizone intoxication in mice. J Neurocytol. 1972;1(4):413\u2013426."},{"issue":"4-5","key":"bib16","series-title":"Mol Cell Neurosci.","first-page":"220","article-title":"Gene expression in brain during cuprizone-induced demyelination and remyelination","volume":"12","author":"Morell P","year":"1998","unstructured":"Morell P, Barrett CV, Mason JL, et al. Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol Cell Neurosci. 1998;12(4-5):220\u2013227."},{"issue":"12","key":"bib17","series-title":"Histol Histopathol.","first-page":"1585","article-title":"De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected","volume":"26","author":"Skripuletz T","year":"2011","unstructured":"Skripuletz T, Gudi V, Hackstette D, Stangel M. De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected. Histol Histopathol. 2011;26(12):1585\u20131597."},{"issue":"13","key":"bib18","series-title":"Int J Mol Sci.","first-page":"10564","article-title":"The cuprizone mouse model: a comparative study of cuprizone formulations from different manufacturers","volume":"24","author":"Beecken M","year":"2023","unstructured":"Beecken M, Baumann L, Vankriekelsvenne E, et al. The cuprizone mouse model: a comparative study of cuprizone formulations from different manufacturers. Int J Mol Sci. 2023;24(13):10564."},{"issue":"1","key":"bib19","series-title":"Metallomics.","first-page":"mfad072","article-title":"Evidence for decreased copper associated with demyelination in the corpus callosum of cuprizone-treated mice","volume":"16","author":"Hilton JBW","year":"2024","unstructured":"Hilton JBW, Kysenius K, Liddell JR, et al. Evidence for decreased copper associated with demyelination in the corpus callosum of cuprizone-treated mice. Metallomics. 2024;16(1):mfad072."},{"issue":"8","key":"bib20","series-title":"Neurochem Res.","first-page":"1029","article-title":"Biochemical changes in cuprizone-induced spongiform encephalopathy","volume":"8","author":"Carey EM","year":"1983","unstructured":"Carey EM, Freeman NM. Biochemical changes in cuprizone-induced spongiform encephalopathy. Neurochem Res. 1983;8(8):1029\u20131044."},{"issue":"1","key":"bib21","series-title":"Neurosci Res.","first-page":"32","article-title":"Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication","volume":"72","author":"Steelman AJ","year":"2012","unstructured":"Steelman AJ, Thompson JP, Li J. Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication. Neurosci Res. 2012;72(1):32\u201342."},{"issue":"1","key":"bib22","series-title":"Mol Med.","first-page":"628","article-title":"Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice","volume":"18","author":"Hagemeyer N","year":"2012","unstructured":"Hagemeyer N, Boretius S, Ott C, et al. Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice. Mol Med. 2012;18(1):628\u2013635."},{"issue":"4","key":"bib23","series-title":"J Mol Neurosci.","first-page":"617","article-title":"Cuprizone-containing pellets are less potent to induce consistent demyelination in the corpus callosum of C57BL\/6 mice","volume":"61","author":"Hochstrasser T","year":"2017","unstructured":"Hochstrasser T, Exner GL, Nyamoya S, Schmitz C, Kipp M. Cuprizone-containing pellets are less potent to induce consistent demyelination in the corpus callosum of C57BL\/6 mice. J Mol Neurosci. 2017;61(4):617\u2013624."},{"issue":"13","key":"bib24","series-title":"Cell Mol Life Sci.","first-page":"1502","article-title":"Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment","volume":"62","author":"Zatta P","year":"2005","unstructured":"Zatta P, Raso M, Zambenedetti P, et al. Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment. Cell Mol Life Sci. 2005;62(13):1502\u20131513."},{"issue":"20","key":"bib25","series-title":"Eur Rev Med Pharmacol Sci.","first-page":"2711","article-title":"Cuprizone-induced demyelination in Wistar rats; electrophysiological and histological assessment","volume":"17","author":"Basoglu H","year":"2013","unstructured":"Basoglu H, Boylu NT, Kose H. Cuprizone-induced demyelination in Wistar rats; electrophysiological and histological assessment. Eur Rev Med Pharmacol Sci. 2013;17(20):2711\u20132717."},{"issue":"4","key":"bib26","series-title":"ASN Neuro.","first-page":"1759091417725174","article-title":"An alternative cuprizone-induced demyelination and remyelination mouse model","volume":"9","author":"Zhen W","year":"2017","unstructured":"Zhen W, Liu A, Lu J, Zhang W, Tattersall D, Wang J. An alternative cuprizone-induced demyelination and remyelination mouse model. ASN Neuro. 2017;9(4):1759091417725174."},{"issue":"4","key":"bib27","series-title":"Behav Res Methods.","first-page":"1149","article-title":"Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses","volume":"41","author":"Faul F","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149\u20131160."},{"issue":"61","key":"bib28","series-title":"J Vis Exp.","first-page":"3393","article-title":"Chronic constriction of the sciatic nerve and pain hypersensitivity testing in rats","author":"Austin PJ","year":"2012","unstructured":"Austin PJ, Wu A, Moalem-Taylor G. Chronic constriction of the sciatic nerve and pain hypersensitivity testing in rats. J Vis Exp. 2012;(61):3393."},{"issue":"3","key":"bib29","series-title":"Brain Pathol.","first-page":"329","article-title":"Quantifying the early stages of remyelination following cuprizone\u2010induced demyelination","volume":"13","author":"Stidworthy MF","year":"2003","unstructured":"Stidworthy MF, Genoud S, Suter U, Mantei N, Franklin RJM. Quantifying the early stages of remyelination following cuprizone\u2010induced demyelination. Brain Pathol. 2003;13(3):329\u2013339."},{"key":"bib30","series-title":"Management of Animal Care and Use Programs in Research, Education, and Testing","first-page":"639","article-title":"Feed and bedding","author":"Carter RL","year":"2017","unstructured":"Carter RL, Lipman NS. Feed and bedding. In: Weichbrod RH, Thomson GAH, Norton JN, editors. Management of Animal Care and Use Programs in Research, Education, and Testing. CRC Press 2017. p. 639\u2013654."},{"issue":"2","key":"bib31","series-title":"J Prev Med Hyg.","first-page":"E255","article-title":"Ethical considerations regarding animal experimentation","volume":"63","author":"Kiani AK","year":"2022","unstructured":"Kiani AK, Pheby D, Henehan G, et al. Ethical considerations regarding animal experimentation. J Prev Med Hyg. 2022;63(2):E255\u2013E266."},{"issue":"5","key":"bib32","series-title":"Brain Behav Immun.","first-page":"699","article-title":"Pain hypersensitivity in rats with experimental autoimmune neuritis, an animal model of human inflammatory demyelinating neuropathy","volume":"21","author":"Moalem-Taylor G","year":"2007","unstructured":"Moalem-Taylor G, Allbutt HN, Iordanova MD, Tracey DJ. Pain hypersensitivity in rats with experimental autoimmune neuritis, an animal model of human inflammatory demyelinating neuropathy. Brain Behav Immun. 2007;21(5):699\u2013710."},{"issue":"1","key":"bib33","series-title":"Brain Behav Immun.","first-page":"92","article-title":"Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental multiple sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy","volume":"23","author":"Sloane E","year":"2009","unstructured":"Sloane E, Ledeboer A, Seibert W, et al. Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental multiple sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. Brain Behav Immun. 2009;23(1):92\u2013100."},{"key":"bib34","series-title":"Adv Neurol.","first-page":"289","article-title":"Hyperexcitability of pathologically myelinated axons and positive symptoms in multiple sclerosis","volume":"31","author":"Rasminsky M","year":"1981","unstructured":"Rasminsky M. Hyperexcitability of pathologically myelinated axons and positive symptoms in multiple sclerosis. Adv Neurol. 1981;31:289\u2013297."},{"issue":"2","key":"bib35","series-title":"J Pharmacol Sci.","first-page":"93","article-title":"LPA5 signaling is involved in multiple sclerosis-mediated neuropathic pain in the cuprizone mouse model","volume":"136","author":"Tsukahara R","year":"2018","unstructured":"Tsukahara R, Yamamoto S, Yoshikawa K, et al. LPA5 signaling is involved in multiple sclerosis-mediated neuropathic pain in the cuprizone mouse model. J Pharmacol Sci. 2018;136(2):93\u201396."},{"issue":"12","key":"bib36","series-title":"Brain Sci.","first-page":"1687","article-title":"Sex differences in the behavioural aspects of the cuprizone-induced demyelination model in mice","volume":"12","author":"Paton KF","year":"2022","unstructured":"Paton KF, Hong S, Biggerstaff A, Kivell BM. Sex differences in the behavioural aspects of the cuprizone-induced demyelination model in mice. Brain Sci. 2022;12(12):1687."},{"issue":"6","key":"bib37","series-title":"Neuropathol Appl Neurobiol.","first-page":"676","article-title":"Lack of cuprizone-induced demyelination in the murine spinal cord despite oligodendroglial alterations substantiates the concept of site-specific susceptibilities of the central nervous system","volume":"37","author":"Herder V","year":"2011","unstructured":"Herder V, Hansmann F, Stangel M, Skripuletz T, Baumg\u00e4rtner W, Beineke A. Lack of cuprizone-induced demyelination in the murine spinal cord despite oligodendroglial alterations substantiates the concept of site-specific susceptibilities of the central nervous system. Neuropathol Appl Neurobiol. 2011;37(6):676\u2013684."},{"key":"bib38","series-title":"Front Mol Neurosci.","first-page":"1007889","article-title":"The role of astrocytes in neuropathic pain","volume":"15","author":"Cheng T","year":"2022","unstructured":"Cheng T, Xu Z, Ma X. The role of astrocytes in neuropathic pain. Front Mol Neurosci. 2022;15:1007889."},{"issue":"2","key":"bib39","series-title":"Drug Dev Ind Pharm.","first-page":"221","article-title":"Enhanced oral bioavailability of a poorly water soluble drug PNU\u201091325 by supersaturatable formulations","volume":"30","author":"Gao P","year":"2004","unstructured":"Gao P, Guyton ME, Huang T, Bauer JM, Stefanski KJ, Lu Q. Enhanced oral bioavailability of a poorly water soluble drug PNU\u201091325 by supersaturatable formulations. Drug Dev Ind Pharm. 2004;30(2):221\u2013229."},{"issue":"39","key":"bib40","series-title":"Curr Pharm Des.","first-page":"3212","article-title":"A recent review on bio-availability enhancement of poorly water-soluble drugs by using bioenhancer and nanoparticulate drug delivery system","volume":"28","author":"Kumar M","year":"2022","unstructured":"Kumar M, Kumar D, Kumar S, Kumar A, Mandal UK. A recent review on bio-availability enhancement of poorly water-soluble drugs by using bioenhancer and nanoparticulate drug delivery system. Curr Pharm Des. 2022;28(39):3212\u20133224."},{"issue":"10","key":"bib41","series-title":"Animals (Basel).","first-page":"754","article-title":"The 3Rs and humane experimental technique: implementing change","volume":"9","author":"Hubrecht RC","year":"2019","unstructured":"Hubrecht RC, Carter E. The 3Rs and humane experimental technique: implementing change. Animals (Basel). 2019;9(10):754."}],"container-title":["Journal of the American Association for Laboratory Animal Science"],"original-title":[],"link":[{"URL":"https:\/\/aalas.kglmeridian.com\/view\/journals\/72010024\/65\/2\/article-p270.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aalas.kglmeridian.com\/downloadpdf\/journals\/72010024\/65\/2\/article-p270.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aalas.kglmeridian.com\/downloadpdf\/journals\/72010024\/65\/2\/article-p270.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T01:59:09Z","timestamp":1777082349000},"score":1,"resource":{"primary":{"URL":"https:\/\/aalas.kglmeridian.com\/view\/journals\/72010024\/65\/2\/article-p270.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":82,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.30802\/aalas-jaalas-25-151","relation":{},"ISSN":["1559-6109"],"issn-type":[{"value":"1559-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}